IGM Biosciences (STU:1K0) Receivables Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. IGM Biosciences's Revenue for the three months ended in Mar. 2024 was €0.46 Mil. IGM Biosciences's average Accounts Receivable for the three months ended in Mar. 2024 was €0.00 Mil.

IGM Biosciences Receivables Turnover Historical Data

The historical data trend for IGM Biosciences's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Receivables Turnover Chart

IGM Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

IGM Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IGM Biosciences's Receivables Turnover

For the Biotechnology subindustry, IGM Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGM Biosciences's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's Receivables Turnover falls into.

IGM Biosciences Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

IGM Biosciences's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	1.953	/ (	(0	+	0)	/	1 )
=	1.953	/	0
=	N/A

IGM Biosciences's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	0.457	/ (	(0	+	0)	/	1 )
=	0.457	/	0
=	N/A

IGM Biosciences (STU:1K0) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

IGM Biosciences Receivables Turnover Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences (STU:1K0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

IGMS:USA

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGM Biosciences (STU:1K0) Headlines

No Headlines